Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG-001 in Amyotrophic Lateral Sclerosis
NCT06315608Phase 2Not yet recruiting
- Sponsor
- MedRegen LLC
- Start
- Jul 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of MRG-001 in amyotrophic lateral sclerosis (ALS), sponsored by MedRegen LLC. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
MRG-001
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06315608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06315608.